Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9317MR)

This product GTTS-WQ9317MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9317MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ477MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ5893MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ4695MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ3466MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ11800MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ15791MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ1882MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ9781MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW